Technology
Health
Biotechnology
Aimmune Therapeutics
$22.439876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$22.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.64 (2.94%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours
Why Robinhood?
You can buy or sell AIMT and other stocks, options, ETFs, and crypto commission-free!
About AIMT
Aimmune Therapeutics, Inc. Common Stock, also called Aimmune Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Read More Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
Employees
215
Headquarters
Brisbane, California
Founded
2011
Market Cap
1.41B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
708.36K
High Today
$22.47
Low Today
$21.81
Open Price
$21.89
Volume
718.62K
52 Week High
$36.12
52 Week Low
$16.95
Collections
Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Research And Development
Food
AIMT News
Price Paid on Robinhood
11% Lower
Right Now
52 Week Low
$19.77
Average Price Paid
$25.09
52 Week High
$36.12
Analyst Ratings
78%
of 9 ratings
Buy
78%
Hold
22%
Sell
0%
AIMT Earnings
-$1.01
-$0.91
-$0.81
-$0.71
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.94 per share
Actual
-$1.01 per share